The new chews incorporate Fr3sh technology, which Virbac says cleanses, cools and addresses the digestive causes of bad breath.
According to the company's research, the new chews provide significant daily breath improvement from Day 1 for a full 24 hours1, as well as continued breath improvement over a 2-week period. 90% of owners highlighted an improvement in bad breath following use of the chews1.
Virbac says the product is also scientifically proven to reduce calculus and plaque when given daily.2
Product Manager Claire Lewis said: "With 2 out of 3 pet owners having a least one dog with bad breath3, we are delighted to be able to add new VeggieDent Fr3sh to the Virbac range of oral healthcare products."
For more information, contact your Virbac Territory Manager.
References:
Dechra says Finilac inhibits prolactin secretion by the pituitary gland and therefore inhibits all prolactin-dependent processes, meaning it can also suppress lactation in bitches and queens.
Finilac, which contains cabergoline (50 microgram/ml), is presented as a liquid which can be given orally or in food. It is available in 3 ml, 10 ml, 15 ml and 25 ml bottles with 1 ml and 2.5 ml syringes included in every pack to ensure accurate dosing.
The dosage is 0.1 ml/kg bodyweight once daily for four to six consecutive days, depending on the severity of the clinical condition. Maximum inhibition of prolactin secretion is achieved after four to eight hours.
Dechra Brand Manager Carol Morgan said: "A false pregnancy can be a distressing condition for an animal and its owner so Finilac offers a fresh approach for cases with more severe symptoms that require veterinary intervention.
"It is easy to administer either directly into the mouth or by mixing with food and it doesn’t need to be transported or stored in the refrigerator, making it ideal as an ‘at home’ treatment that can be administered by owners."
Fitzpatrick Referrals has carried out a world-first procedure in which an American Bulldog was fitted with a prosthetic hip and femur with a special in-growth attachment which effectively re-attaches the tendons and muscles to the artificial limb.
The procedure took place after 8 year old Roly was diagnosed with cancer in his rear hind leg earlier this year. It involved a highly complex two-hour operation, during which Dr Noel Fitzpatrick, a neuro-orthopaedic veterinary surgeon, replaced the cancerous femur bone and hip joint with a specially constructed artificial prosthesis, while re-attaching the musculature and realigning the relative position of the joint to restore perfect movement to the dog.
The prosthesis was designed through a collaboration between Professor Gordon Blunn, Head of the Centre for Bio-Medical Engineering at UCL's Institute of Orthopaedics and Musculoskeletal Science; veterinary surgeon Noel Fitzpatrick and Jay Meswania from specialist implant manufacturer OrthoFitz.
Professor Blunn said: "What is significant about the design is the way in which it sandwiches tissue and metal together overlaying the gluteal muscles onto the top of the endoprosthetic femur - alternating tendon, synthetic Dacron mesh, tendon, synthetic Dacron mesh, tendon and finally trabecular metal - which has a honeycomb surface resembling a series of small chambers. In this way, the hope is that the Sharpeys fibres which attach tendons of muscles to the bone will grow into the trabecular metal surface and permanently adhere to it."
"This truly remarkable achievement was made possible through the convergence of biomechanics, biology and surgical innovation," said Noel Fitzpatrick. "We tapped into the evidence provided by the CT and MRI scanners we have in place at the practice, so that the data collected about Roly during clinical diagnosis was used to design and construct an artificial femur which exactly mirrored his original limb. It has been constructed rather like a telescope - one section fitting inside the adjoining section, so that we get maximum flexibility and traction during motion."
Noel added: "Hip replacement is common here. We do more than 50 a year, on animals as small as a cat or a Chihuahua. But this hip replacement was special, and to my knowledge, the first of its kind in the world. It's important though to emphasise that this technology must only be employed when it is in the best interests of the individual patient. It's not enough to be able to do something; it must be done for the right reason in every case without exception. It must be ethically right. It's also important to emphasise that Roly will probably not live for a normal lifetime because bone cancer generally spreads to the lungs over time in spite of chemotherapy. However, this technology is equally applicable for dogs and cats affected by trauma who will likely live longer. My job is to look after my patients as best I can and to be honest with their guardians and give them options. What I do is provide pain free functional quality of life for as long as my patient is alive. That's important and that's special, but the decision must remain with each and every individual animal owner".
According to the team, this development also has potentialy life-changing implications for human patients such as motorcycle accident victims, where a key challenge to recovery may be successfully re-attaching the kneecap tendon onto the top of the tibia in the lower leg, and injured sports players with ruptured repairing ruptured tendons.
Click here to view the x-rays of this case in the VetSurgeon Gallery.
Royal Canin has launched two new skincare diets.
'Hypoallergenic Wet' is a wet adaptation of its 'Hypoallergenic' range of diets, providing variety for the nutritional management of dogs with adverse food reactions. 'Anallergenic' dry food is for the dietary management of dogs with even the most severe dietary allergy.
'Hypoallergenic Wet' contains soy protein hydrolysate, so it can either be fed as a complete diet or interchanged and used as an addition to Hypoallergenic, Hypoallergenic Moderate Calorie or Hypoallergenic Small Dog. The wet food, available in a 400g can, can be recommended for short term feeding (for an elimination diet strategy) or for the lifelong nutritional management of dogs with adverse food reactions. Royal Canin says it is designed to be highly digestible through its low molecular weight peptides and is also appropriate for the dietary support of dogs with inflammatory bowel disease, chronic diarrhoea and Exocrine Pancreatic Insufficiency (EPI).
'Anallergenic' follows in the footsteps of Hypoallergenic but goes further - offering both hydrolysed proteins and a pure carbohydrate source, to which exposure is limited and therefore allergy would be rare. The diet comprises a unique protein source composed exclusively of free amino acids and very low molecular weight oligopeptides. Much like the Hypoallergenic range, Anallergenic is also formulated with essential fatty acids to help support skin health and a complex of nutrients to help maintain the barrier effect of the skin.
The fully balanced diet - suitable for the nutritional support of adult dogs either short or long-term - has proven results with 100% of dogs in a Royal Canin study showing significant improvement in their skin condition.
Gudi Stuttard BVSc MRCVS, one of Royal Canin's Veterinary Support Managers, said: "These two new products join our well-established 'Hypoallergenic' range, as well as our recently launched 'Skin Care' diets - for the nutritional management of dogs with dermatosis unrelated to food intolerance or allergy.
"By building on our portfolio of veterinary skin care diets, we aim to further strengthen our DermAlliance campaign, which is dedicated to assisting in the improvement of skin care knowledge in general veterinary practice."
Please visit www.royalcanin.co.uk for more information.
The hearing concerned three separate charges against Mr Mallon. The first charge related to his treatment of a Labrador named Bailey on 15 September 2016 in which he was alleged to have euthanased the animal without the owner’s consent, after having been called out to her home following concerns about Bailey’s arthritis.
The second charge related to failure to keep adequate clinical records for Bailey between 14 March 2015 and 30 September 2016.
The third charge related to failing to respond adequately to communications regarding Bailey’s treatment from his owner between 15 September 2016 and 6 January 2017.
At the outset of the hearing, Mr Mallon admitted the charge relating to keeping inadequate clinical records. However, he disputed the College’s evidence regarding euthanasing Bailey without his owner’s consent. He claimed to have had previous discussions with the owner’s husband about euthanasia six months prior to the event, that he had been informed that the owner had mentioned a possible need for euthanasia in a phone call earlier that day and that, on attending the premises, the owner’s mother had mentioned a need to put Bailey down. During the course of the hearing, Mr Mallon accepted that these incidents could not have reasonably amounted to consent.
The Committee also heard and accepted evidence that the owner’s mother, who was present when Mr Mallon visited, had wished to contact her daughter to inform her about the planned euthanasia but that Mr Mallon proceeded to euthanase the animal regardless. The Committee also noted there was no contemporaneous clinical records nor any signed consent form for the procedure. Furthermore, the Committee found no evidence that there was a need to put Bailey down immediately and no reason why Mr Mallon could not have waited until the owner was present and had given consent.
Regarding the third charge, the Committee heard that the communications between Mr Mallon and the owner amounted to a telephone call on 15 September and a letter from the owner dated 16 September in which she asked a number of questions about Bailey’s treatment. The Committee accepted that, during the phone call, the owner had made a number of threats to Mr Mallon that had caused him to be fearful for himself and his property. Furthermore, the Committee found that there were a number of points in the subsequent letter to which he could have responded and the Committee noted that, when he was giving evidence, Mr Mallon expected the owner to apologise to him and withdraw the threats before he would engage with her complaint. The Committee therefore found the charge proved.
After finding the charges proved the Committee then went on to consider whether, individually and cumulatively, they constituted serious professional misconduct. It found this to be the case in respect of all three charges. Commenting on the first charge Jane Downes, chairing the Committee and speaking on its behalf, said: "He should have allowed the owner to come to an informed decision. He had an opportunity to obtain informed consent and he failed in this regard. By failing to take this opportunity he overrode the possibility of allowing [the owner] the right to choose whether to be present or to discuss Bailey’s prognosis."
The Committee then went on to consider the sanction for Mr Mallon and heard from a number of clients and professional colleagues who spoke to his skill, care, passion for animal welfare and high standing in his community. The Committee also considered 30 written testimonials from clients. In mitigation, the Committee also considered Mr Mallon’s otherwise unblemished 30-year career, the fact it was a single isolated event related to one animal and the fact that there was no evidence of systemic or repeated behaviour.
Jane Downes added: "The Committee concluded that the appropriate and proportionate sanction is a reprimand in this case. The Committee is confident that Mr Mallon will not repeat the conduct identified in this case again. The Committee wishes to advise Mr Mallon of the need to reflect on the outcome of this case, the need to have clear communication systems in place at this practice that are effective so as to avoid any possibility of miscommunication. The Committee further advises Mr Mallon of the need to be familiar and comply with all aspects of the Code [of Professional Conduct for Veterinary Surgeons] and its associated guidance, particularly in respect of keeping clinical records, informed consent and effective complaint management."
The authors say that study seeks to redress the lack of evidence-based information that has so far been published on the epidemiology and clinical management of non-neoplastic anal sac disorders (ASD).
The study, which was carried out within the RVC’s VetCompass programme, focused especially on identifying breeds with increased or reduced risk of anal sac disorders.
The breeds at greatest risk of an anal sac disorder compared with crossbreeds included Cavalier King Charles spaniel, King Charles spaniel and Cockapoo.
Conversely, breeds at reduced risk included larger breed dogs including Boxer, German Shepherd Dog and Lurcher. Flat-faced (brachycephalic) breeds such as Shih Tzu had 2.6 times the risk for anal sac disorders compared to long-skulled breeds such as Border Collies. Spaniel-types, Dachshund-types and Poodle also showed increased risk for anal sac disease.
The study identified 2,372 anal sac disorder cases from a population of 104,212 dogs attending VetCompass participating practices during 2013.
Other findings included:
Dr Dan O’Neill, Senior Lecturer, Companion Animal Epidemiology, at the RVC, and author of the paper, said: “During two decades in first opinion practice, anal sac problems in dogs were a routine daily presentation for me. However, when I searched the literature to find evidence on the best way to treat these dogs or even on which breeds were at most risk, there was almost no information available. It seemed back then that only problems that were severe enough to be referred to universities in large numbers were researched.
"As a result, vets in first opinion practice generally had to work out for themselves what seemed to be the best treatment in these cases. It is refreshing now to see research on common problems in dogs under first opinion veterinary care being reported. Owners and vets needs this evidence vitally.”
Anette Loeffler, Associate Professor of Veterinary Dermatology at the RVC and co-author of the paper, said: "This study shines a spotlight on critically important area of veterinary practice: antibiotic usage. Twenty percent of dogs presenting with an anal sac disorder received antibiotics even though diagnostic criteria for anal sac infection or proof of efficacy of antibiotic treatment are lacking.
"At a time when antimicrobial resistance presents one of the biggest threats to human and animal health, this highlights an urgent need for further study of these disorders in order to improve dog welfare but also to help vets in making responsible antibiotic treatment decisions in the interest of public health.”
Zenalpha provides restraint, sedation and analgesia during non-invasive, non-painful or mildly painful procedures and examinations intended to last no more than 30 minutes2.
It is administered intramuscularly and takes effect within 5-15 minutes1, 2.
Dechra says patients also recover more rapidly2, potentially avoiding hospitalisation and allowing them to get home sooner.
Zenalpha contains the active ingredients 0.5 mg/ml medetomidine hydrochloride and 10mg/ml vatinoxan hydrochloride.
Medetomidine is an alpha-2 agonist used for its sedative and analgesic properties.
Vatinoxan is a peripherally selective alpha-2 antagonist which Dechra says has limited penetration across the blood-brain barrier, so it works to antagonise only the alpha-2 receptors located in the periphery, reducing cardiovascular side effects without impacting the quality of sedation or analgesia.
In a study of 223 dogs1 comparing a traditional alpha-2 agonist with Zenalpha, Zenalpha was found to minimise cardiovascular side effects while preserving reliable sedation and analgesia.
Claire Westoby, brand manager at Dechra said: ‘The next generation of alpha-2 agonists have evolved to provide the same effective and reliable sedation and analgesia, but with reduced cardiovascular side effects and a reduced chance of vomiting.
"This improves the sedation experience for the canine patient, as well as reducing the associated stress commonly experienced by veterinary teams and dog owners.”
Matt Gurney FRCVS, an RCVS and EBVS European Specialist in Veterinary Anaesthesia and hospital director at Anderson Moores, said: “It is really exciting to see the launch of an innovative new product, especially one with a unique mechanism of action that will improve the sedation experience for the vet team and our patients.
"Zenalpha not only provides a solution to cases where IV placement is not possible and a rapid onset IM option is required, but it also offers a rapid and complete recovery which ensures that dogs can be reunited with their owners and return home as soon as possible.”
Zenalpha is presented in a 10 ml glass vial in individually packed cardboard boxes.
For more information: www.dechra.co.uk/zenalpha or contact your local Dechra territory manager.
To watch Matt Gurney’s ‘Zennovation in sedation – the next generation of alpha-2 agonists’: www.dechra.co.uk/academy.
References
The report also revealed the devastating impact on overworked veterinary staff, with some left in tears by abusive owners venting their frustration at being unable to find care for their animal.
Anecdotally, the problems highlighted by ITV News are being seen elsewhere in the country, with more and more vets now starting to question whether or not the current requirement to provide out of hours care is sustainable in a world where there are more clients who increasingly expect flea treatment advice and other non emergency situations to be dealt with at 3:00am in the morning.
Various solutions have been proposed in a forum discussion on VetSurgeon.org, including the removal of the requirement to provide an OOH service, for the RCVS to give vets the confidence to say no to non emergencies, a change to the CoPC to require vets to provide emergency care within 24 hours, not 24 hours a day, a requirement for new grads to undertake OOH as part of their PDP, and/or a requirement for OOH centres to have 3 vets on duty at any one time (which could improve working conditions).
As the ITV report pointed out, the fundamental issue is one of a shortage of supply over demand, for which there is no overnight fix. However, many feel that reducing the demands of providing OOH could ease the situation considerably.
Zoetis has launched UlcerGold (omeprazole) for the treatment - and prevention of recurrence - of gastric ulcers in horses and foals, presented in a syringe suitable for foals from four weeks of age and horses from 70 to 700kg.
Equine Gastric Ulceration Syndrome (EGUS) is a serious and common condition affecting horses and foals.2,3 Approximately 90% of racehorses, 60% of performance horses, 37% of leisure horses and 50% of foals have been shown to be affected.2,4,5 The condition is associated with injury to the mucosa of the oesophagus, stomach and duodenum, with prolonged exposure to gastric acid thought to be the primary cause.2,3 Risk factors include stress, intense exercise, a high-grain diet, intermittent feeding and illness.2,3 EGUS can have a profound impact on a horse's condition and performance and can ultimately be life threatening, especially in foals.3,5 It is a challenging condition to diagnose as the clinical signs are often vague and not always present.3 Gastroscopy is the only method currently available for a definitive diagnosis and treatment is usually based on acid suppressive therapy to allow ulcer healing.2
UlcerGold is indicated to treat and prevent the recurrence of gastric ulcers in horses, administered once-daily for 28 consecutive days at the full dose of 4mg/kg bodyweight followed by the reduced dose of 1mg/kg bodyweight for a further 28 days.1 It contains omeprazole, a proton pump inhibitor that suppresses gastric acid secretion.1,2 One syringe contains enough UlcerGold for a horse weighing up to 700kg. It can be used for foals as young as four weeks of age that weigh over 70kg and for breeding stallions.
Zoetis says UlcerGold is supported by a comprehensive gastroscope training programme, pricing model, client support and communications plan to ensure that it is a strong asset to veterinary businesses.
Penny McCann, Equine Product Manager, Zoetis UK Ltd, said: "UlcerGold is an exciting addition to our equine POM-V portfolio. We have designed a training, education and business programme to help practices make sure they get the best from our new product, not only in terms of gastric ulceration treatment but also practice health."
Corona Detect is a first-line screening tool for detecting exposure to feline coronavirus (FCoV). It can be coupled with the Idexx FIP Virus RealPCR to follow up coronavirus-positive cats exhibiting clinical signs suspected to be FIP. The Idexx FIP Virus RealPCR evaluates for mutations of feline coronavirus to the pathogenic FIPV biotype.
Idexx says that this new two-tier diagnostic approach will help veterinary surgeons rule out or positively diagnose FIP, a condition which has hitherto been extremely difficult and frustrating to diagnose.
Simon Wootton, Idexx’s Companion Animal Group’s Northern European Marketing Manager said: "FIP is a terrible disease, so being able to screen and either confirm or rule out exposure to FCoV is an important additional step in the diagnosis options available to vets. With the ability to screen in minutes, practitioners will be able to decide whether to perform confirmatory and potentially invasive tests for the specific FIPV mutations. This obviously brings benefits to aid pet owners."
Further information is available on the company’s website – www.idexx.eu
Pedigree has announced that it has raised over £160,000 to help the thousands of dogs abandoned every year in the UK, through its charitable initiative, The Pedigree Adoption Drive 2011.
Pedigree says its fundraising comes at a crucial time, as rescue centres' facilities across the country are severely suffering under the strain of the highest level of dog abandonment in over a decade.
The Pedigree Adoption Drive, which launched in mid-October, aims to raise awareness of the ever-increasing issues of dog abandonment and funds for the hundreds of rescue centres across the country that work tirelessly to find these dogs new loving homes.
Now in its fourth year, the campaign called upon dog lovers everywhere to show their support, by taking part in the world's first virtual dog walk around the web. In addition, consumers got involved in a host of other activities - donating via text message and online, to help the Drive reach this year's grant total.
The funds raised this year will be distributed through grants to 90 rescue homes across the country - including three special grants of £15,000 given to Bath Cats and Dogs Home, £20,000 given to North Clwyd Animal Rescue and £25,000 given Birmingham Dogs Home. Every grant will be put towards projects aimed at making tomorrow better than today for dogs - including the refurbishment of dilapidated kennel blocks, desperately needed veterinary facilities and the supply of essential surgical equipment.
TV presenter and vet Steve Leonard, who is the ambassador of this year's campaign, said: "The money raised from this year's Pedigree Adoption Drive is a great example of how we can achieve so much together to help take steps towards tackling the issue of dog abandonment. The grants awarded to rescue centres this year will make a big difference in helping to find many rescue dogs, the loving homes they deserve."
Katie Wragg, Pedigree Adoption Drive Brand Manager said: "In the last four year's we've raised over £1million for rescue centres supporting the country's abandoned dogs and despite the tough economic climate, the amazing public reaction has enabled us to really make a difference to the lives of abandoned dogs across the UK and help give them a bright future."
For more information on the campaign log on to: http://www.pedigreeadoptiondrive.com/
Animalcare has announced the launch of Fungiconazol (ketoconazole), the UK's only veterinary licenced antifungal tablet for dogs, indicated for the treatment of ringworm.
Each Fungiconazol tablet contains 200 or 400mg of ketoconazole, to be administered at a dosage of 10mg per kg bodyweight once daily. Each tablet can be split into quarters or halves, allowing accurate treatment for dogs from 5kg (¼ x 200mg tablet daily) to 60kg (1½ x 400mg tablet daily) and beyond. The hypoallergenic chicken flavoured tablets mean that Fungiconazol is also suitable for dogs with food allergies or atopic dermatitis.
Animalcare Product Manager Tony Liepman said "This is a great addition to our antimicrobial range, and shows once again that it’s possible for us to be innovative without breaking anyone's budget. With the supply of the first and only licensed canine antifungal tablet on the market, we have ensured that all veterinary practices have access to Animalcare’s Technical Support department for further advice on treatment or its use in their patients."
Both 200mg and 400mg presentations of Fungiconazol, in 100 tablet blister packs, are now available from wholesalers.
For further information contact Animalcare on 01904 487687, or speak to your regional Animalcare representative (found at www.animalcare.co.uk/contact-us).
The group, which was founded over 70 years ago, now employs over 300 people, more than 85% of whom are female. Many occupy senior and leadership positions: 6 out of 13 of the partners are female.
Wendy Furness, a Partner at Scarsdale Vets said: "Scarsdale Vets represents a microcosm of how women’s roles could be in a world of gender equality in business.
"Here we have people in every role that you can imagine, from client-facing roles such as client care advisors, vets and nurses, to people that make the business function happen, such as marketing and finance managers.
"We want women to be inspired to be who they want to be. There are many roles that some people still first think of as male dominated, such as surgeons and farm or equine vets.
"However, we at Scarsdale Vets are challenging assumptions like these and looking for opportunities to make all roles visible to women.”
Wendy added: "Having women in leadership and senior roles is essential if women at the start of their careers are to succeed. We can be there to inspire the next generation to strive for these positions, if that is what they want, and see that it is made possible. We can also stand up and be counted if and when bias based on gender is observed."
To mark International Women’s Day, Scarsdale Vets is filling its social media channels with positive images of women, working in the diverse roles within the practice, challenging stereotypes about the veterinary roles available to women, influencing others positively, and celebrating the successes of the women in their team.
https://www.facebook.com/ScarsdaleVets/posts/2097073290308906
Photo: Rose Jackson MRCVS, a farm animal vet at Scarsdale Markeaton. Courtesy Scarsdale Vets.
Purina carried out a survey earlier this year which revealed the different ways British cat owners manage sensitivity to cat allergens2. They included removing the cat when sensitivities to allergens act up (76%), restricting the cat to specific places in the home (75%), using special cat products on the cat such as dander removers or allergen sprays (64%), bathing the cat (56%) and taking the cat to a groomer (52%).
92% also use a high-quality vacuum cleaner, 66% put covers on their furniture and 26% clean their home and furniture daily to remove traces of cat hair.
Dr Ebenezer Satyaraj, PhD, immunologist for Nestlé Purina Research and lead investigator on the research that led to the development of Pro Plan LiveClear, said: “Many people think that cat hair or dander is the allergen, but it’s actually what’s on it – the major cat allergen called Fel d 1, a protein that cats produce naturally in their saliva.” 3,4
All cats produce Fel d 1, regardless of breed, age, hair length, sex or body weight, but at differing levels.4-6 When cats groom themselves, Fel d 1 gets on the hair and skin through the saliva and with shedding, it eventually gets into the home environment. Feld d 1 attaches itself to any surface it comes into contact with and remains in houses for over a year or more.
Purina says Pro Plan LiveClear contains a specific protein, sourced from eggs, which binds itself to the Fel d 1 and safely neutralises it in the cat’s mouth, thereby reducing the amount of active allergen shed in the environment 7,8.
In a study, feeding Pro Plan LiveClear was shown to reduce the allergens on cat hair and dander by an average of 47%, starting in the third week of daily feeding7.
There have been no studies as yet which have tested the effect of this allergen reduction on human symptoms, but Purina says anecdotal evidence from consumers who have tried the product has been positive thus far.
Amena Warner, Head of Clinical Services at Allergy UK said: "Amena Warner, Head of Clinical Services at Allergy UK said: "There are a number of ways in which cat owners try to manage their exposure to cat allergens and keep their symptoms at bay, including taking antihistamines, using inhalers for quick symptoms relief as sensitivity to cat allergens is often linked to allergy-related asthmas, regularly cleaning and hoovering, bathing and grooming the cat by non-allergic family members. And if these measures do not work, current medical advice is often to relinquish the pet to limit exposure to the allergens.
"Every cat is unique though, and so the level of Fel d 1 they produce varies, just as every person's sensitivity level to these allergens is different. That is why there is no ‘one size fits all’ way to manage exposure to cat allergens. Every little bit helps so a combination of management tools often works best to help reduce cat allergens in your home - the combination is unique to your lifestyle. We welcome the development of Pro Plan LiveClear, which when used as part of a cat allergen management regime, could be a meaningful extra tool for affected households.”
Purina says Pro Plan LiveClear is not intended to replace other cat allergen-reduction strategies but to add another measure that can help reduce the cat allergen burden in cat households.
Pro Plan LiveClear is available at Pets at Home retail stores and from the Purina online shop as a complete life-stage range with six products tailored for Kitten, Adult and Adult 7+.
'Hany’s Heartbreak' was a gorily realistic representation of a dog’s heart infected with Dirofilaria Immitis, baked by vet students Anna Burrows, Caitlin Glover, Chloe Tredinnick and Liberty Daly.
It pulled in votes from all over the world including Australia and the US, Saudi Arabia, Germany, Italy and the Caribbean.
The winning bakers said: "We chose to bake this cake as we wanted to make something that we could make look as realistic as possible and as gruesome.
"Our parasitology lecturer, Hany, inspired us to use the D. Immitis parasite as our theme to promote the message of how detrimental and possibly fatal some animal parasites can be! We had a great time baking it and enjoyed the looks of disgust that people who saw it gave. We promise it tastes better than it looks! Our key message to everyone is to PLEASE WORM YOUR PETS!"
The categories for baking inspiration this year were Transport to Campus, Scrumptious Science, Blue Planet and a Showstopper section. Sir David Attenborough and Pixar characters Nemo and Dory were among the other stars of the show, with colourful cakes on an environmental theme also winning prizes.
One of this year’s judges was Dr Wendela Wapenaar, Associate Professor at the Nottingham Vet School. Wendela said: “It’s been another great year for the Sutton Bonington Bakeoff. It was impressive to see how some bakers took on the challenging topics for this year; winning cakes were covering topics such as global warming, environmental pollution in addition to the more gory aspects of veterinary medicine."
GRAM (Guidance for the Rational use of AntiMicrobials) is a 500-page guide written by a panel of 10 independent European experts from the fields of microbiology, pharmacology and dermatology, all of whom are specialists in internal medicine, surgery and epidemiology. Based on rational use with compliance at the forefront, GRAM provides tools for improved diagnosis and positive treatment outcomes.
The guide consists of 37 disease fact sheets, 29 practical recommendations and six reference synopses. It features a range of topics including:
Andy Forsyth, senior technical veterinary advisor at Ceva said: "Antimicrobial resistance continues to be a concern in both human and animal health. GRAM will help educate veterinary professionals on how they can play their part in creating sustainable antibiotic use."
To request a copy of GRAM or for further information on sustainable antibiotic use, contact your local Ceva Animal Health territory manager.
Dr Fures was convicted of driving with excess alcohol in the Dublin Criminal Courts of Justice in December 2018.
Later, when renewing his UK RCVS registration, Dr Fures told the RCVS Chief Investigator that on the day of his offence, he'd been on a flight from Frankfurt to Dublin which suffered engine failure, causing the pilot to perform a forced emergency landing in Amsterdam. There, he claimed, the passengers switched to an airworthy plane for the rest of the journey, during which he had several drinks to calm his nerves.
In a remarkably detailed and complex investigation, the RCVS Chief Investigator rang Lufthansa and discovered that the flight had not suffered engine failure and had flown direct from Frankfurt to Dublin without incident.
In May and July 2020, the RCVS Chief Investigator wrote to Dr Fures setting out the result of his investigations and research. In his responses Dr Fures accepted that his memory of the incident was wrong.
At the outset of the hearing Dr Fures made an application to the Committee enter into undertakings to voluntarily remove himself from the UK Register and to not apply to re-join. However, the Committee did not accept these undertakings in part on the basis that he was not of retirement age and intended to continue to practise in Ireland.
The Committee considered that if it were to accept his undertakings, then there would be no judgement or findings that could be passed on to the Veterinary Council of Ireland for consideration via its own disciplinary procedures.
Ian Arundale, chairing the Committee and speaking on its behalf, said: “The Committee decided that this is a case in which the public interest, confidence in the profession, and, potentially, the welfare of animals, demands that there be a full hearing, with determinations made by the Disciplinary Committee."
The Committee then went on to consider the facts of the case.
Dr Fures admitted that he had supplied the RCVS with false information about his conviction for drink driving but denied that this was dishonest at the time that he supplied the information. He accepted that the information he provided was wrong, in that his flight between Frankfurt and Dublin, while delayed by just over an hour, did not have to land in Amsterdam as he had previously claimed.
He said that his false statement was based on misremembering the circumstances and that he had genuinely believed his statement was true at the time it was made to the RCVS. He said that, due to shame over his conviction and the negative impact it had on the life of him and his family, he had created a false memory of the circumstances.
However, the Committee was not persuaded that there was any other explanation in this case, other than that Dr Fures deliberately and dishonestly gave false information to the RCVS, to excuse his behaviour.
The Committee then considered if the admitted and proven charges amounted to serious professional misconduct.
Ian said: “The Committee was of the view that Dr Fures’ actions in dishonestly giving false details to his regulator was serious. While it was the case that there was no actual harm or risk to animals arising out of his conduct, the Committee took into account that the dishonest account was given deliberately.
“In addition, it was sustained, in that it was relied upon and expanded upon on several occasions when the College sought further clarity. Dr Fures had the opportunity to correct the situation, and give the truthful account, but he did not do so. The dishonesty was designed to achieve personal gain to Dr Fures, in that he wished to minimise the actions which the College may take against him, and, in consequence, safeguard his career.
“Dr Fures’ action in dishonestly giving false information to his regulator struck at the heart of his obligation, as a registered professional, to be open and honest with his regulator. This obligation is necessary to allow the College, as regulator, to carry out its crucial and statutory functions in ensuring that it investigates concerns properly.”
In considering the sanction for Dr Fures, the Committee took into account the mitigating factors, including the fact that there were no previous regulatory findings against Dr Fures or any previous conviction for dishonesty, that he had demonstrated remorse for his actions, that there was no actual harm or risk of harm to any animal, that no concerns raised about Dr Fures’ practice, that there was no repetition of the dishonest conduct and that he had demonstrated some insight.
However, in terms of aggravating factors it considered that there was deliberate and sustained dishonesty and that he had sought personal gain as a result of his actions.
After considering various options, the Committee decided that a reprimand and warning as to future conduct was the most appropriate sanction for Dr Fures.
The full findings for the case can be found at: www.rcvs.org.uk/disciplinary
Duoflect contains a new formulation of fipronil and (s)-methoprene which, according to the company, offers a 100% longer duration of action against fleas in cats (eight weeks), and a 13% longer duration in dogs (nine weeks) than the market-leading fipronil combination.
Ceva says the Duoflect's duration of action against ticks is 150% longer in cats (5 weeks) and 50% longer it cats (six weeks) than the market-leading competitor.
Duoflect acts against both adult fleas on the animal and immature flea stages in the environment and it can also be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Duoflect is available in free-standing pipettes for easier administration and handling of the pet. The pipettes are packed in child-resistant aluminium blisters to reduce the risk of accidents at home.
Nicki Glen, marketing project manager for Duoflect at Ceva Animal Health said: "Recent research1 has revealed that two main factors in prescribing parasitic control products are the length of action and the increased efficacy against fleas.
"Duoflect's new strength formulation provides a longer duration of action than the market-leading fipronil combination, while its efficacy is proven through 13 recent laboratory and field trials1."
Duoflect is competitively priced and is available in boxes of three or six pipettes and in five presentations: small cats (1-5kg), large cats (>5kg) and small dogs (2-10kg) and medium dogs (10-20kg), large dogs (20-40kg) and extra large dogs (40-60kg). It is suitable for cats and dogs from eight weeks of age.
Ceva Animal Health has produced a range of supporting marketing materials including client leaflets.
For more information, contact your local Ceva Animal Health territory manager or call Ceva’s head office on 01494 781510.
Reference
Zoetis says the new vaccine, which is also the first in Europe to be administered orally, offers increased comfort for dogs, and a smooth consultation room experience for both dog owners and veterinarians. It has a 12-month duration of immunity.
Dr. Eileen Ball, Global Veterinary Medical Lead for Companion Animal Infectious Diseases for Zoetis, said: "Versican Plus Bb Oral provides robust protection along with an innovative and smooth means of administration. The new oral delivery brings a more positive experience for dogs, owners and vets. We expect this new option for vaccination will lead to an increase in recommendations for Bordetella prevention, better vaccination compliance, and ultimately a healthier dog population.
"Nearly all dogs are at risk of CIRDC, and Bordetella is a common, but preventable pathogen. Adding Versican Plus Bb Oral to vaccination protocols offers CIRDC protection for dogs. Vets can propose this new vaccination to pet owners at an annual wellness visit in the knowledge that they will be creating a less stressful experience for the pet and owner."
Zoetis has set up The European Canine Infectious Respiratory Disease Advisory Board – made up of veterinary specialists from across Europe – to provide guidance and advice on the product’s launch.
Board member, Professor Emeritus Michael J. Day, University of Bristol, a consultant to Zoetis, said: "The CIRDC has a multifactorial pathogenesis, involving environmental and lifestyle factors and numerous potentially causative organisms. CIRDC is not just a cough picked up in kennels. It can be spread in any space occupied by multiple dogs, including grooming parlours, dog day care establishments or dog parks. The pathogens have not disappeared over time and CIRDC is prevalent throughout Europe, with Bordetella bronchiseptica remaining a commonly identified agent in infected dogs.
"I think it is exciting for European veterinarians now to have another option in the way they deliver non-core Bordetella protection. There will be different situations depending on circumstances in which either an oral, intranasal, or injectable route of administration will be most appropriate."
Zoetis says Versican Plus Bb Oral will rolled out across Europe from November 2019 to October 2020.
Royal Canin has announced that it will be launching Multifunction, a new range of veterinary diets designed for cats and dogs experiencing - or at risk of - multiple health conditions.
According to the company, 35% of cats and dogs meet this description1 and it can be difficult for veterinary surgeons and nurses to recommend a diet which meets all their needs when one diet can't address multiple nutritional priorities.
Officially being launched at BSAVA, Multifunction diets are designed to provide an option for the nutritional management of cats and dogs with more than one condition, thereby eliminating the need to decide which of two conditions take precedence when developing a nutritional assessment for patients.
The company says that the new diets have been developed by combining existing Veterinary Diet formulae. The range includes:
Marianne Lomberg, Veterinary Marketing Manager said: "As a company, one of the things we are proud of is looking at the pet as a whole, rather than just a clinical condition on legs. For this reason we combine the features of our standard veterinary diets to provide support for other issues that a pet may develop. For example, our Urinary Moderate Calorie diet is lower in calories than standard diets in order to help prevent weight gain in animals predisposed to obesity as a result of living indoors or being neutered. However, until now, we have not been able to provide vets with a diet for a pet that has already been diagnosed with two equally serious concurrent conditions, such as lower urinary tract disease and obesity. Our new Multifunction diets do just this.
"Pets suffering from more than one condition also generally require more regular veterinary care, too, and a unique new ordering system for these diets helps facilitate ongoing contact between the pet owner and their veterinary practice every time they order a new bag of food. More information about the diets and the ordering system will be available on the ROYAL CANIN, stand: 611."
Multifunction will only be available through veterinary practices and all bags will be personalised, including the practice logo and patient name. Further information on how to sign up to the product programme will be available at the show stand.
For more information, visit: http://new.vetportal.royalcanin.co.uk/products/multifunction-2/
Mark, who graduated from Cambridge University in 1997, has a broad interest in internal medicine but particularly enjoys the challenges posed by gastrointestinal, endocrine, haematology and renal medicine.
He has a PhD in Neuroscience at the University of Cambridge and after completing his PhD he took a residency in Small Animal Medicine at Cambridge, followed by four years in a private specialist practice in the south of England.
Mark was then appointed Clinical Associate Professor in Small Animal Internal Medicine at the Nottingham Veterinary School, where he was responsible for running the final year medicine rotation along with lecturing to all years of the veterinary course.
He was also in charge of the school’s small animal intern and residency programmes in addition to supervising both undergraduate and post-graduate research students.
Mark has also been involved in national and international investigations into canine breed-related diseases such as canine cancer, canine and feline haematology, canine endocrine disease and the development of novel non-invasive biomarkers to help diagnose both simple and complex medical diseases.
Outside work, Mark is a seven-guitar-owning-musician, a race-winning cyclist and a keen runner with a personal best of one hour twenty five minutes for a half marathon. What a relief for the rest of us mere mortals to hear there's something he's rubbish at: he says he swims 'like a brick'.
Mark said: "I’m excited to be joining the outstanding team at Willows who deliver such exceptional care to pets and their owners and such an outstanding service to the referring veterinary surgeons.
"It is a wonderful opportunity for me and I’m really looking forward to making my own contribution to their continued success."
Written by members of BSAVA Scientific Committee, together with specialists in internal medicine and neurology, the document explains that there are limited studies showing beneficial effects of CBD, and those that there are need to be interpreted with caution as they involved small sample sizes and used unlicensed products which may have contained other components which could have influenced the results.
The document also explains that legally, CBD products must be prescribed by a veterinary surgeons and not used instead of a medication with proven efficacy.
Caroline Kisielewicz, BSAVA Scientific Committee member and one of the authors of the document said: “Information regarding the effects of cannabinoids on animals is predominantly at the stage of pre-clinical testing of individual substances in mice, rats and guinea pigs. There are limited clinical studies looking at the effects of CBD in dogs, and no reported studies in cats.
"There are many reports describing possible beneficial effects and therapeutic potential in humans, and subsequently pet owners may ask their vet about using cannabinoids to treat veterinary patients. This document aims to provide a broad overview of the available evidence base and legal position in the UK for veterinary team members."
BSAVA President, Ian Ramsey added: "The development of this information is in direct response to an increased interest in the use of CBD to treat cats and dogs. Furthermore, the guidance supports BSAVA’s mission to promote excellence in small animal practice through community, education and science."
The BSAVA position on CBD can be accessed here: https://www.bsavalibrary.com/content/chapter/10.22233/9781910443514.chap8#html_fulltext.
Bacteria isolated from human dental units analysed in other studies included Pseudomonas Sp, Mycobacteria and Legionella.
Bob said: "The Care Quality Commission (CQC) would have no hesitation in shutting down practices with the level of contamination we have seen. The dangers are real and significant for our teams as well as for our patients.
"Part of the problem is that dental units produce aerosols which can carry the bacteria into the depths of the lungs, bypassing normal defence mechanisms. Endotoxin levels have also been shown to be very high in untreated units, potentially resulting in problems when surgical extractions are performed.
Bob added: "The good news is that the biofilms which harbour the bacteria are treatable - but simply adding a little chlorhexidine will not do the trick."
Working with industry leaders, www.VetDentist.info has produced a Starter Kit for veterinary practices, which Bob says will clear biofilms and also provides a safe maintenance solution for ongoing use.
Bob says the cost of keeping your dental unit’s water lines safe for staff and patients is around 25-40p per day. Practices can also sign up for a regular monitoring scheme.
For more information and to get a VetDentist Starter Kit, visit www.VetDentist.info.
Stelfonta is licensed for the treatment of non-resectable, non-metastatic (WHO staging1) subcutaneous mast cell tumours (MCTs) located at or distal to the elbow or the hock, and non-resectable, non-metastatic cutaneous MCTs in dogs. Tumours must be less than or equal to 8cm3 in volume and must be accessible to intratumoural injection.
The company says that a single intratumoural treatment has been seen to destroy the tumour completely in 75% of observed cases.
The active ingredient in Stelfonta is tigilanol tiglate, a compound extracted from Fontainea picrosperma, a shrub found in the Australian rain forest. According to the company, it works largely through specific protein kinase c (PKC) activation, in which it locally stimulates the immune system, resulting in destruction of the tumour and the tumour’s blood supply, followed by rapid healing of the site with minimal scarring.
Virbac says that generally, dogs do not require sedation or local or general anaesthesia during treatment.
Dr Neil Mottram MRCVS, Technical Product Manager at Virbac said: "Stelfonta is an innovative yet simple treatment which provides a high tumour elimination rate, rapid healing and a speedy return to a good quality of life for the pet. In the cases studied, the tumour was destroyed in seven days and full wound healing observed in 96.5% of cases, with no significant adverse effects on the dog.
“The effects of Stelfonta really do need to be seen to be believed."
The journal publishes original peer-reviewed papers of international or global significance that improve the veterinary care and welfare of domestic cats.
Until this year, access to JFMS for most veterinary practitioners was dependent on membership to the International Society of Feline Medicine (ISFM) or the American Association of Feline Practitioners (AAFP), or a separate paid subscription.
Now that the journal is open access, there are no restrictions on who can access the journal and all articles past and present are free to view.
The journal's editors say that making it open access greatly improves their ability to improve the health and welfare of cats by providing high-quality peer-reviewed information.
The AAFP and ISFM say they have already seen the positive impact this has had, with low- and middle-income countries now accounting for a quarter of the 20 most common geographic locations for visitors to the JFMS website.
Head of ISFM Nathalie Dowgray said: "Transitioning JFMS to an open access journal helps ISFM fulfil our parent charity’s (International Cat Care) mission of creating a cat friendly world through ensuring the latest knowledge in feline medicine and welfare is available to the global veterinary community."
For those interested in submitting to JFMS, authors can get a 50% discount on the article processing charge until 4 July 2023; after this date, a 22% discount will be in place for authors who are a member of ISFM or the AAFP.
Click here for more information about submitting an article to JFMS: https://journals.sagepub.com/author-instructions/JFM
https://journals.sagepub.com/home/jfm